SAPHNELO Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

SAPHNELO (Anifrolumab), a first-in-class type I interferon receptor blockade monoclonal antibody for moderate-to-severe SLE, is projected to see strong market growth through 2034 across major markets. The drug generated approximately $483 million in the first nine months of 2025 and has been approved in over 70 countries. However, the FDA issued a Complete Response Letter in February 2026 for the subcutaneous formulation, which AstraZeneca is working to address.